These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 21082510)

  • 1. Ovarian hyperstimulation syndrome prevention strategies: Luteal support strategies to optimize pregnancy success in cycles with gonadotropin-releasing hormone agonist ovulatory trigger.
    Engmann L; Benadiva C
    Semin Reprod Med; 2010 Nov; 28(6):506-12. PubMed ID: 21082510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gonadotropin-releasing hormone agonist trigger: the way to eliminate ovarian hyperstimulation syndrome--a 20-year experience.
    Kol S; Itskovitz-Eldor J
    Semin Reprod Med; 2010 Nov; 28(6):500-5. PubMed ID: 21082509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of gonadotropin-releasing hormone agonists and antagonists on luteal function.
    DiLuigi AJ; Nulsen JC
    Curr Opin Obstet Gynecol; 2007 Jun; 19(3):258-65. PubMed ID: 17495643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GnRHa to trigger final oocyte maturation: a time to reconsider.
    Humaidan P; Papanikolaou EG; Tarlatzis BC
    Hum Reprod; 2009 Oct; 24(10):2389-94. PubMed ID: 19608565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Agonist trigger: what is the best approach? Agonist trigger with aggressive luteal support.
    Engmann L; Benadiva C
    Fertil Steril; 2012 Mar; 97(3):531-3. PubMed ID: 22245529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of low dose hCG for luteal support after triggering ovulation with a GnRH agonist in cases of polyfollicular development.
    Krause BT; Ohlinger R
    Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):87-92. PubMed ID: 16377065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
    Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM
    Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gonadotropin-releasing hormone agonist for ovulation trigger - OHSS prevention and use of modified luteal phase support for fresh embryo transfer.
    Castillo JC; Haahr T; Martínez-Moya M; Humaidan P
    Ups J Med Sci; 2020 May; 125(2):131-137. PubMed ID: 32366146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The gonadotropin-releasing hormone antagonist protocol--the protocol of choice for the polycystic ovary syndrome patient undergoing controlled ovarian stimulation.
    Kol S; Homburg R; Alsbjerg B; Humaidan P
    Acta Obstet Gynecol Scand; 2012 Jun; 91(6):643-7. PubMed ID: 22428986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gonadotropin-releasing hormone agonist (GnRHa) trigger - State of the art.
    Dosouto C; Haahr T; Humaidan P
    Reprod Biol; 2017 Mar; 17(1):1-8. PubMed ID: 28215488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oocyte maturation employing a GnRH agonist in combination with low-dose hCG luteal rescue minimizes the severity of ovarian hyperstimulation syndrome while maintaining excellent pregnancy rates.
    Radesic B; Tremellen K
    Hum Reprod; 2011 Dec; 26(12):3437-42. PubMed ID: 21997895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose human chorionic gonadotropin versus estradiol/progesterone luteal phase support in gonadotropin-releasing hormone agonist-triggered assisted reproductive technique cycles: understanding a new approach.
    Garcia-Velasco JA; Motta L; López A; Mayoral M; Cerrillo M; Pacheco A
    Fertil Steril; 2010 Dec; 94(7):2820-3. PubMed ID: 20673892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Luteal phase supplementation after gonadotropin-releasing hormone agonist trigger in fresh embryo transfer: the American versus European approaches.
    Humaidan P; Engmann L; Benadiva C
    Fertil Steril; 2015 Apr; 103(4):879-85. PubMed ID: 25681859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A gonadotropin releasing hormone agonist trigger of ovulation with aggressive luteal phase support for patients at risk of ovarian hyperstimulation syndrome undergoing controlled ovarian hyperstimulation.
    Liang IT; Huang HY; Wu HM; Wang HS; Yu HT; Huang SY; Chang CL; Soong YK
    Taiwan J Obstet Gynecol; 2015 Oct; 54(5):583-7. PubMed ID: 26522115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Avoiding ovarian hyperstimulation syndrome with the use of gonadotropin-releasing hormone agonist trigger.
    Fatemi HM; Garcia-Velasco J
    Fertil Steril; 2015 Apr; 103(4):870-3. PubMed ID: 25724740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The luteal phase after GnRH-agonist triggering of ovulation: present and future perspectives.
    Humaidan P; Papanikolaou EG; Kyrou D; Alsbjerg B; Polyzos NP; Devroey P; Fatemi HM
    Reprod Biomed Online; 2012 Feb; 24(2):134-41. PubMed ID: 22197130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absence of luteal phase defect and spontaneous pregnancy in IVF patients despite GnRH-agonist trigger and "freeze all policy" without luteal phase support: a report of four cases.
    Gurbuz AS; Deveer R; Ozcimen N; Ozcimen EE; Lawrenz B; Banker M; Garcia-Velasco JA; Fatemi HM
    Gynecol Endocrinol; 2016; 32(1):18-20. PubMed ID: 26487486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual trigger of oocyte maturation with gonadotropin-releasing hormone agonist and low-dose human chorionic gonadotropin to optimize live birth rates in high responders.
    Griffin D; Benadiva C; Kummer N; Budinetz T; Nulsen J; Engmann L
    Fertil Steril; 2012 Jun; 97(6):1316-20. PubMed ID: 22480822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal gonadotropin-releasing hormone agonist (GnRHa) for luteal-phase support following GnRHa triggering, a novel approach to avoid ovarian hyperstimulation syndrome in high responders.
    Bar-Hava I; Mizrachi Y; Karfunkel-Doron D; Omer Y; Sheena L; Carmon N; Ben-David G
    Fertil Steril; 2016 Aug; 106(2):330-3. PubMed ID: 27114332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of "triggers" using leuprolide acetate alone or in combination with low-dose human chorionic gonadotropin.
    Shapiro BS; Daneshmand ST; Garner FC; Aguirre M; Hudson C
    Fertil Steril; 2011 Jun; 95(8):2715-7. PubMed ID: 21550042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.